- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Bristol-Myers Squibb "Will Win Big with Melanoma Combination Immunotherapy"
June 23, 2015.
Following by Bristol-Myers Squibb's (BMS) presentation of data relating to Opdivo/Yervoy at this year's ASCO meeting, GlobalData has stated that, once approved, this combination of immunotherapies to treat metastatic melanoma "will shape the therapeutic landscape".
GlobalData analyst Fenix Leung said that the therapy "is a clear winner in the melanoma treatment market" and expects BMS "to bag peak-year sales of $3.28 billion for both the monotherapies and the combination therapy across the eight major markets of the US, France, Germany, Spain, Italy, UK, Japan, and Australia in 2023".
Companies with immuno-oncology drug are teaming up in the hope of repeating BMS’ success - for example, Merck with Amgen, Dynavax, and Syndax to find a potential Keytruda (pembrolizumab)-containing combination for melanoma - but Leung warned that unless they are able to develop an immunotherapy combination that is more efficacious and/or less toxic than Opdivo/Yervoy, BMS is likely to dominate the melanoma treatment market for a long time.
Source: GlobalData
